Karo Bio AB Granted 3.8 MSEK From Vinnova
STOCKHOLM--(BUSINESS WIRE)--Karo Bio AB (publ) (STO:KARO) has been awarded another SEK 3.8 million from Vinnova for the preclinical development of an ERbeta agonist for the treatment of different forms of cancer. In total, Karo Bio has thus been granted SEK 4.8 million for the project from Vinnova.
Help employers find you! Check out all the jobs and post your resume.